News|Videos|November 6, 2023
Factors in Frontline Treatment Decision Making for Endometrial Cancer
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.
Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.
Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.
Interim DUO-E data showed longer median survival with chemotherapy plus durvalumab and olaparib maintenance that did not reach significance.
Readers share their opinions on some of the most talked-about gynecologic cancer abstracts they’re looking forward to seeing at ESMO 2026.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
T-DXd Plus Pertuzumab Improves Outcomes in HER2+ Breast Cancer With Brain Metastases
3
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Yields Clinically Meaningful in Platinum-Resistant Ovarian Cancer
4
ASTRO Guideline Backs Hypofractionation Across Risk Groups in Localized Prostate Cancer
5